These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32583733)

  • 1. Challenges in Evaluating Safety and Efficacy in Drug Development for Rare Diseases: A Review for Pharmacists.
    Shah KK; Kogut S; Slitt A
    J Pharm Pract; 2021 Jun; 34(3):472-479. PubMed ID: 32583733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
    Karas L; Lu CY; Agrawal PB; Asgari MM
    J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
    Mease C; Miller KL; Fermaglich LJ; Best J; Liu G; Torjusen E
    Orphanet J Rare Dis; 2024 Feb; 19(1):86. PubMed ID: 38403586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience.
    Lomash RM; Shchelochkov O; Chandler RJ; Venditti CP; Pariser AR; Ottinger EA;
    Hum Gene Ther; 2023 Mar; 34(5-6):217-227. PubMed ID: 36694456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.
    Hwang TJ; Bourgeois FT; Franklin JM; Kesselheim AS
    Health Aff (Millwood); 2019 Feb; 38(2):313-319. PubMed ID: 30715972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-finding studies in drug development for rare genetic diseases.
    Wang L; Wang J; Feng J; Doi M; Pepe S; Pacanowski M; Schuck RN
    Orphanet J Rare Dis; 2022 Apr; 17(1):156. PubMed ID: 35382851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs.
    Bannister JB
    Fordham Law Rev; 2018 Mar; 86(4):1889-921. PubMed ID: 29993206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
    Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
    Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025).
    Rim MH; Karas BL; Barada F; Dean C; Levitsky AM
    Am J Health Syst Pharm; 2024 Aug; 81(16):733-738. PubMed ID: 38831753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA's Office of Orphan Products Development: providing incentives to promote the development of products for rare diseases.
    Patel S; Miller Needleman KI
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):387-393. PubMed ID: 31278433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating access to treatments for rare diseases.
    Dunoyer M
    Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.
    Wu J; Yang Y; Yu J; Qiao L; Zuo W; Zhang B
    Orphanet J Rare Dis; 2023 Nov; 18(1):368. PubMed ID: 38017575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E
    Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME
    Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R&D and market size: Who benefits from orphan drug legislation?
    Gamba S; Magazzini L; Pertile P
    J Health Econ; 2021 Dec; 80():102522. PubMed ID: 34530381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.